Skip to main content
NKTX
NASDAQ Life Sciences

Nkarta's NKX019 Hits 83% Myositis, 86% SSc Responses With Zero CRS/ICANS/GvHD

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.45
Mkt Cap
$124.049M
52W Low
$1.48
52W High
$3.72
52W Position info
2.0% below low
Off High info
61% below high
Rel. Volume info
2.6× avg
Market data snapshot near publication time

NKTX is trading near its 52-week low of $1.48 (2.0% below the low) on elevated volume (2.6× avg).

Summary

Nkarta reported initial NKX019 data showing 83% myositis and 86% systemic sclerosis response rates at the 4 billion-cell dose, with no CRS, ICANS, IEC-HS or GvHD across 40 patients. Dosing is now being compressed and FDA talks on a registrational path are in preparation.


Key Events · Product Development and Regulatory · NKTX

  • Initial NKX019 Efficacy Data Released

    At 4 billion cells/dose, 5 of 6 myositis patients (83%) with at least three months of follow-up achieved moderate or major TIS responses; 6 of 7 systemic sclerosis patients (86%) achieved rCRISS-25 and 5 of 7 (71%) rCRISS-50 by Day 90.

  • Clean Safety Across 40 Patients

    Across five autoimmune indications and three dose levels, there were no cases of CRS, ICANS, IEC-HS or GvHD, no treatment discontinuations due to adverse events and no deaths; infusion-related reactions occurred in 5 patients (12.5%), mostly Grade 1.

  • Dosing Compressed, 6B Dose Planned

    Host T-cell recovery before the Day 7 dose prompted a protocol amendment to dose on Days 0, 2 and 4, with a planned 6 billion-cell evaluation alongside the 4 billion-cell cohort.

  • FDA Talks and 1H 2027 Milestones

    Nkarta anticipates upcoming FDA interactions on registrational pathways in myositis and systemic sclerosis, with additional follow-up and a registrational dose plan (4B vs 6B) expected in the first half of 2027.


Analysis · NKTX · Life Sciences

Here is the first look at NKX019's actual clinical results in autoimmune disease, and they are strong on both axes that matter for a cell therapy: efficacy and safety. At the 4 billion-cell dose, 5 of 6 myositis patients (83%) with at least three months of follow-up hit moderate-or-major TIS responses, while 6 of 7 systemic sclerosis patients (86%) reached rCRISS-25, with 5 of 7 (71%) at rCRISS-50 and a median 15-point mRSS drop by Day 90. Just as important, across 40 treated patients there were no cases of CRS, ICANS, IEC-HS or GvHD and no discontinuations or deaths — the toxicities that make rival CAR-T therapies hospital-bound. That safety profile is what supports outpatient, community-rheumatologist administration, the commercial thesis here. Protocols have been amended to compress dosing to Days 0, 2 and 4, and the company will test 6 billion cells, with FDA registrational discussions upcoming and a dose-selection plan in 1H 2027. Caveats: these are small, early, open-label numbers with a September 18, 2026 cutoff, and some patients received outside immunomodulatory therapy. With the stock near its 52-week low, the readout is the clearest re-rating event the program has had.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NKTX was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124M. The 52-week trading range was $1.48 to $3.72. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NKTX - Latest Insights

NKTX
Aug 10, 2026, 4:32 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.36
Real-time Price: $1.46 info
Change: -$0.900 (-38%) info
Market Cap: $124.049M info
NKTX
May 12, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $3.10
Real-time Price: $1.46 info
Change: -$1.64 (-53%) info
Market Cap: $124.049M info
NKTX
May 12, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.28
Real-time Price: $1.46 info
Change: -$1.82 (-55%) info
Market Cap: $124.049M info
NKTX
Apr 15, 2026, 5:21 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $2.41
Real-time Price: $1.46 info
Change: -$0.950 (-39%) info
Market Cap: $124.049M info
NKTX
Apr 03, 2026, 5:29 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.32
Real-time Price: $1.46 info
Change: -$0.860 (-37%) info
Market Cap: $124.049M info